120 related articles for article (PubMed ID: 34733843)
41. Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma.
Peng J; Zou D; Gong W; Kang S; Han L
Oncoimmunology; 2020; 9(1):1734156. PubMed ID: 32158626
[TBL] [Abstract][Full Text] [Related]
42. Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1.
Liu L; Ruiz J; O'Neill SS; Grant SC; Petty WJ; Yang M; Chen K; Topaloglu U; Pasche B; Zhang W
Mol Cancer; 2018 Apr; 17(1):81. PubMed ID: 29650000
[TBL] [Abstract][Full Text] [Related]
43. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
44. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
45. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
46.
Zhang W; Shang X; Yang F; Han W; Xia H; Liu N; Liu Y; Wang X
Front Oncol; 2022; 12():867788. PubMed ID: 35574406
[TBL] [Abstract][Full Text] [Related]
47. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
48. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
Front Oncol; 2019; 9():1161. PubMed ID: 31750249
[No Abstract] [Full Text] [Related]
49. Development and Validation of a Ferroptosis-Related Gene Signature for Overall Survival Prediction in Lung Adenocarcinoma.
Tian Q; Zhou Y; Zhu L; Gao H; Yang J
Front Cell Dev Biol; 2021; 9():684259. PubMed ID: 34307361
[No Abstract] [Full Text] [Related]
50. Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy.
Zhou X; Liu Y; Xiang J; Wang Y; Wang Q; Xia J; Chen Y; Bai Y
Front Immunol; 2021; 12():665002. PubMed ID: 34367132
[TBL] [Abstract][Full Text] [Related]
51. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
52. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.
He B; Dong D; She Y; Zhou C; Fang M; Zhu Y; Zhang H; Huang Z; Jiang T; Tian J; Chen C
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32636239
[TBL] [Abstract][Full Text] [Related]
53. Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes.
Dancik GM; Theodorescu D
PLoS One; 2014; 9(1):e85249. PubMed ID: 24465512
[TBL] [Abstract][Full Text] [Related]
54. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
55. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.
Lv Y; Huang Z; Lin Y; Fang Y; Chen Z; Pan L; Zhang Y; Xu Z
Oncoimmunology; 2019; 8(10):e1629260. PubMed ID: 31646073
[No Abstract] [Full Text] [Related]
56. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
57. Integrative analysis and experiments to explore angiogenesis regulators correlated with poor prognosis, immune infiltration and cancer progression in lung adenocarcinoma.
Cai S; Guo X; Huang C; Deng Y; Du L; Liu W; Yang C; Zhao H; Ma K; Wang L; He J; Yu Z
J Transl Med; 2021 Aug; 19(1):361. PubMed ID: 34419075
[TBL] [Abstract][Full Text] [Related]
58. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
59. DPYSL2 as potential diagnostic and prognostic biomarker linked to immune infiltration in lung adenocarcinoma.
Wu YJ; Nai AT; He GC; Xiao F; Li ZM; Tang SY; Liu YP; Ai XH
World J Surg Oncol; 2021 Sep; 19(1):274. PubMed ID: 34517904
[TBL] [Abstract][Full Text] [Related]
60. Predictive Value of
Chen XJ; Ren AQ; Zheng L; Zheng ED
Front Immunol; 2021; 12():664847. PubMed ID: 33953726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
